Cost Per Responder for Ixekizumab and Other Biologic Drugs Approved for the Treatment of Moderate-To-Severe Plaque Psoriasis in Italy

Global and Regional Health Technology Assessment - Italy
doi 10.1177/2284240318822289
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Aboutscience Srl

Related search

Pss33 - Secukinumab as First Biologic Treatment: A Cost Per Responder Analysis Compared With Licensed Biologics, for Moderate to Severe Psoriasis in Argentina

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss16 - Cost Per Responder Analysis of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Versus Non-Biologic Systemic Therapy in the Treatment of Moderate to Severe Plaque Psoriasis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss17 - Cost Per Responder Analysis of Brodalumab Compared With Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss31 - Cost Per Responder of Secukinumab Compared to Other Biologics in Moderate-To-Severe Plaque Psoriasis From the Private Payer Perspective in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Spotlight on Ixekizumab for the Treatment of Moderate-To-Severe Plaque Psoriasis: Design, Development, and Use in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2017English

Psy103 - Modelling Average Cost and Cost-Per-Responder for Biological Treatments for Moderate-To-Severe Plaque Psoriasis With Dose Escalation and Real-World Drug Survival

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

PSS14 Cost-Effectiveness of Biologic Therapies for the Treatment of Moderate to Severe Psoriasis in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Pss32 - Cost-Effectiveness of Brodalumab for the Treatment of Moderate to Severe Plaque Psoriasis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

540 Rapid Response in PASI, sPGA, and BSA Measures for Patients With Moderate-To-Severe Plaque Psoriasis With Ixekizumab

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy